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sample t-test to evaluate glycemic control associated with CANA. RESULTS: A total 
of 9,805 CANA users were identified, among which 6,571 (67%) were in the CANA100 
group (mean age: 59; 48% female; 75% white; mean Charlson Comorbidity Index 
[CCI]: 1.8; mean Diabetes Complications Severity Index [DCSI]: 0.9) and 3,234 (33%) 
were in the CANA300 group (mean age: 57; 44% female; 75% white; mean CCI: 1.6; 
mean DCSI: 0.8). Before the index date, 98% and 97% of patients were prescribed 
≥ 1 antihyperglycemic agent, with a mean number of 5.6 and 5.5 antihyperglyce-
mic agents per patient in the CANA100 and CANA300 groups, respectively. In the 
6 months following CANA initiation, mean HbA1c values decreased from 8.4% to 
7.9% (p< 0.0001) among CANA100 patients and from 8.5% to 7.8% (p< 0.0001) among 
CANA300 patients. CONCLUSIONS: Patients treated with CANA in the real-world 
setting often received multiple prior diabetes treatments and had uncontrolled 
HbA1c levels. Patients taking CANA significantly improved their HbA1c values, with 
numerically greater improvement in those with CANA 300mg.
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OBJECTIVES: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor recently 
approved for T2DM treatment, which does not require dose adjustment in 
patients with renal or hepatic impairment. The patterns of treatment adher-
ence among patients initiating linagliptin in routine care settings are largely 
unknown. METHODS: Within a large, nationwide US health insurance database 
(Optum Clinformatics), we identified T2DM patients ≥ 18 years initiating linagliptin 
or other NIDMs from May 2011 through June 2012. Patients were followed for adher-
ence measures for up to 12 months. Findings were replicated in a propensity score 
(PS)-matched population and in another US commercial health insurance database 
(MarketScan). RESULTS: Of 155,345 T2DM patients initiating a NIDM, 46.8% initiated 
metformin, followed by sulfonylureas (21.8%), and sitagliptin (11.9%). Linagliptin was 
initiated by 2,820 patients (1.8%). Linagliptin and saxagliptin initiators had the high-
est proportion of days covered [PDC] (77.5% and 75.8%, respectively) and medication 
possession ratio [MPR] (0.67 and 0.66). Similarly, compared to initiators of other 
agents, these patients less frequently filled only one dispensing of their medica-
tion [1DISP] (15.0% for linagliptin and 15.7% for saxagliptin), and more persisted on 
therapy at 12 months [P12] (51.5% and 49.8%). Metformin initiators had PDC = 70.4%, 
MPR = 0.57, 1DISP = 23.0%, and P12 = 35.5%. The lowest adherence measures were 
observed among initiators of meglitinides (PDC 64.0%; MPR 0.46; 1DISP 32.4%; P12 
22.6%), glitazones (PDC 68.8%; MPR 0.51; 1DISP 30.2%; P12 28.4%) and GLP-1 receptor 
agonists (PDC 68.3%; MPR 0.54; 1DISP 23.3%; P12 33.6%). These patterns of adherence 
were similar after PS-matching and in MarketScan data, suggesting differences in 
adherence were not due to patient or health insurer characteristics. CONCLUSIONS: 
Compared to other NIDMs, patients initiating linagliptin (along with saxagliptin) 
exhibit greater adherence to therapy. The observed patterns of adherence are not 
likely to be due to patient or health insurer characteristics.
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OBJECTIVES: Chronic activation of the pathological arm of the renin angiotensin 
system (RAS) contributes to lung fibrosis, chronic inflammation, impaired immune 
function and oxidative stress in type 2 diabetic (T2D) patients. Studies have shown 
that diabetic patients treated with angiotensin-converting-enzyme (ACE) inhibitors 
or angiotensin II receptor blockers (ARBs) achieve a reduction in all-cause mortal-
ity. Our objective is to determine if RAS-modifying medications have a beneficial 
impact on lung health and immunity in T2D patients. METHODS: A retrospec-
tive analysis was conducted using claims data from a US commercial insurance 
company. The study groups consisted of T2D patients taking either: ACE inhibi-
tors, ARBs, control [diuretics or calcium-channel blockers (CCBs)], or combination 
drugs (ACE inhibitors/diuretics, ARBs/diuretics, ACE inhibitors/CCBs, ARBs/CCBs). 
Logistic regression analyses were performed to estimate the association between 
exposure to each treatment and the incidence of respiratory complications: pneu-
monia and influenza (PNIN) or chronic obstructive pulmonary disease and allied 
conditions (COPDAC). RESULTS: A total of 171,857 patients were identified. During 
the 4.5 year of follow-up, patients treated with ACE inhibitors had lower incidence 
of PNIN [8.84%, odds ratio (OR) 0.91, 95% CI 0.86-0.94] or COPDAC (17.1%, OR 0.86, 
95% CI 0.84-0.90), compared to patients treated with control drugs (9.93% and 19.71% 
respectively). ARBs patients also exhibited a lower rate of PNIN (8.89%, OR 0.91, 95% 
CI 0.86-0.97) and COPDAC (17.1%, OR 0.86, 95% CI 0.82-0.90) compared to control. 
Patients treated with combination drugs exhibited the lowest incidence of PNIN 
(8.14%, OR 0.86, 95% CI 0.82-0.91) and COPDAC (16.15%, OR 0.82, 95% CI 0.80-0.86) 
relative to control patients. CONCLUSIONS: Preliminary results suggest that there is 
a measurable benefit from RAS-modifying medications on pulmonary health in T2D 
patients. There are no notable differences in patients treated with either ACE inhibi-
tors or ARBs. Further, there may also be added benefit of using combination therapy.
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FPG levels (MD -2.17 [CI 95% -2.44, 1.91, p< 0.001]) and body weight (MD-2.91 [95% 
CI -3.50, -2.32]) after 26 weeks as compared to placebo. The risk of occurrence of 
urinary tract infections (RR 1.25 [95% CI 0.80, 1.94]), genital mycotic infections 
among males (RR 8.73 [CI 95% 2.07, 36.72, p= 0.003]) and females (RR 4.37 [CI 95% 
2.03, 9.38, p= 0.0002]) was higher in the canagliflozin arm as compared to placebo 
arm. CONCLUSIONS: Canagliflozin significantly decreases HbA1c, FPG levels 
and body weight while increasing the risk of urinary tract infections and genital 
mycotic infections as compared to placebo among patients with inadequately 
controlled T2DM.
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OBJECTIVES: To examine the relationship between different anti-diabetic thera-
pies (DPP-4, metformin and sulfonylureas) and risk of acute pancreatitis among 
type 2 diabetic patients in Taiwan, and explore each drug’s dose-response relation-
ship. METHODS: We derived a nationwide retrospective cohort of patients with 
type 2 diabetes in Taiwan. The inclusion criteria are adult diabetic patients with 
continuous baseline enrollment, new users of the studied drugs, and without miss-
ing demographics. There were 4,113/101,498/44,772 DPP-4/Metformin/Sulfonylurea 
users. Adjusted hazards ratios for pancreatitis associated with DPP-4, derived from 
Cox Proportional Hazard models with propensity score weighting, were estimated; 
dose-response analyses were also conducted. RESULTS: DPP-4 was statistically 
significantly associated with a decreased risk of acute pancreatitis compared to 
sulfonylureas (adjusted HR: 0.36, 95% CI: 0.17-0.75) but not metformin (adjusted HR: 
0.67, 95% CI: 0.32-1.41); metformin was statistically significantly associated with a 
lower risk of pancreatitis than sulfonylurea (adjusted HR: 0. 53; 95% CI, 0.37-0.76). 
In addition, low-dose metformin was statistically significantly associated with a 
lower risk of pancreatitis compared to high-dose metformin (HR: 0.65; 95% CI, 0.44-
0.97). CONCLUSIONS: Our findings suggest that sulfonylureas may potentially be 
associated with an increased risk of pancreatitis compared to DPP-4 or metformin. 
This population-based cohort study extends the previous evidence in an ethnic 
Chinese type 2 diabetic cohort. Studies with longer follow up, larger sample sizes 
and more precise capture of confounders may be needed to determine the risk of 
pancreatitis associated with Incretin based therapies.
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OBJECTIVES: Real-world evidence on adherence to glucagon-like peptide-1 recep-
tor agonist (GLP-1RA) in elderly or disabled patients is limited. Patient adherence to 
an antidiabetic regimen is a clinical challenge when considering the medical com-
plexities of T2DM in elderly patients and other comorbidities associated with aging. 
GLP-1RA therapies such as exenatide once weekly (QW) and liraglutide once daily 
(QD) are an increasingly used class of drugs with proven efficacy and tolerability. 
The current study examined adherence to medication in patients age ≥ 65 years 
with T2DM initiating a GLP-1RA. METHODS: The study used medical and pharmacy 
claims between 2010 and 2013 for Medicare members in a US health plan diagnosed 
with T2DM and were new initiators of either exenatide QW (n= 537) or liraglutide QD 
(n= 3673) during that time frame and were continuously enrolled for 6 months pre- 
and post-index. Proportion of Days Covered (PDC) ≥ 80% was used to determine post-
index adherence. Logistic regression models controlled for baseline demographics, 
comorbidities and T2DM treatments. RESULTS: A significantly higher percentage of 
patients on exenatide QW had a PDC ≥ 80% (43.2%) vs liraglutide QD (35.0%, χ 2, p< .01). 
Adjusted results indicated patients on liraglutide QD were 20.1% (p< .01) less likely to 
be adherent than patients on exenatide QW. Two other significant factors associated 
with lower adherence were: evidence for cardiovascular disease and plan type. The 
mean proportion of days covered showed patients on exenatide QW had a slightly 
higher medication possession rate of GLP1-RA compared with patients on liraglutide 
QD: 63.5% vs. 61.5% (ns). CONCLUSIONS: Results from this retrospective study sug-
gest that overall adherence to GLP-1RAs was low, but was better with exenatide QW. 
Patients 65 years and older treated with exenatide QW had a significantly higher 
adherence rate compared to liraglutide QD. Further research is needed to validate 
these findings in other patient populations.
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OBJECTIVES: Canagliflozin (CANA), an agent that inhibits sodium glucose co-
transporter 2, has been shown to improve glycemic control in patients with T2DM 
in clinical trials. The current study described the early clinical characteristics and 
glycemic control of T2DM patients receiving different doses of CANA following 
approval of CANA in a real-world setting. METHODS: Adults with ≥ 1 diagnosis for 
T2DM and ≥ 6 months of clinical activity before first CANA prescription (index) were 
identified in the Cegedim Strategic Data US electronic medical records database, in 
which 60% of contributors are primary care providers. Patients were stratified by 
their first CANA daily dose (100mg [CANA100] or 300mg [CANA300]) observed in the 
database. Patients’ clinical characteristics were assessed descriptively and HbA1c 
levels at baseline and 6 months after the index date were compared using paired 
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OBJECTIVES: The increase in the prevalence of type-2 diabetes has resulted in a 
substantial increase in the utilization of oral diabetes drugs in the US. This study 
assessed changes in the safety profile of the oral diabetes medications approved by 
the US Food and Drug Administration (FDA) as of December 31, 2014. METHODS: 
Regulatory information for oral diabetes medications as of December 31 was derived 
from the FDA webpage. Label information was extracted from the FDA webpage 
and paper copies of the PDR Book. Drugs were classified according to the WHO 
anatomical therapeutic chemical classification. Descriptive statistics and chi-square 
tests were used for the analysis. RESULTS: The FDA listed a total of 44 oral diabetes 
medications as of December 31, 2014, including 30 single active ingredients and 
14 fixed-dose combinations. Three of the single active ingredients and 1 of the 
combinations were discontinued from the market as of December 31, 2014. In total, 
15.9% of the drugs were approved before 1990, 22.7% in the 1990s, 36.4% in the 2000s, 
and 25.0% in 2010-2014. The main changes in safety profile of the drugs included 
in the study occurred in contraindications (changes in 50.0% of the drugs), limita-
tions (38.6%), warning and precautions (36.4%), and black box warnings (20.5%). 
Additionally, changes also occurred in the indications approved by the FDA for 31.8% 
of the drugs. Changes in safety profile did not significantly varied according to the 
year of approval of a drug; however, drugs approved in the period 2010-2014 had 
a lower number of safety changes due to the limited time these drugs have been 
in the market. CONCLUSIONS: This study found substantial changes over time in 
the safety profile of oral diabetes drugs. Future research should evaluate the effect 
of changes in the safety profile of oral diabetes medication on patient outcomes.
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OBJECTIVES: Despite being the most efficacious blood glucose lowering therapy, 
the majority of patients on basal insulin do not achieve adequate glycemic control 
(HbA1c< 7.0%), increasing the risk of complications. A patient-adjusted mealtime 
insulin-dosing algorithm was recently validated in a randomized clinical trial 
(AUTONOMY) and demonstrated statistically significant and clinically meaningful 
reductions in HbA1c (-1.0%). The goal of our study was to estimate the longer term 
economic outcomes of this clinical trial treatment effect in a representative sample 
of US patients with Type 2 diabetes. METHODS: We utilized a validated Monte Carlo 
microsimulation model to compare patients initiating the AUTONOMY daily (Q1D) 
titration algorithm upon HbA1c drift to those delaying initiation. Outcomes mod-
eled included mean HbA1c, diabetes-related complications, mortality, and associ-
ated costs over 10 years. Treatment effects were modeled from AUTONOMY clinical 
trial results. The setting for the economic analysis was representative of the care 
delivered within the general population of patients utilizing insulin within the US 
(NHANES). Sensitivity analyses included factors such as time horizon, discount 
rate, and baseline HbA1c. RESULTS: Patients initiating self-adjusted bolus titra-
tion upon HbA1c drift had better outcomes over the 10 years: decreases of -1.3% in 
severe hypoglycemic events, -2.8% in myocardial infarction or cardiac events, -1.8% 
in stroke, -6.9% in blindness, -12.4% in lower extremity amputations, and -1.7% in 
mortality. These patients were estimated to have a small increase in pharmacy 
BACKGROUND: Chronic kidney disease (CKD) is highly prevalent in type 2 diabetes 
mellitus (T2DM) population. However, information regarding recent temporal trends 
and prevalence within key demographic subgroups are lacking. OBJECTIVES: To 
estimate the prevalence of CKD stages in T2DM over time and within demographic 
subgroups. METHODS: Individuals ≥ 18 years old with T2DM were identified from 
the US National Health and Nutrition Examination Survey (NHANES) 2007-2012 via 
either self-reported diabetes or antidiabetic medication use. Individuals with type 
1 diabetes, pregnancy, and with missing serum creatinine lab value, age, gender, or 
race were excluded. CKD was staged based on KDIGO 2012 guidelines as: 1= esti-
mated glomerular filtration rate (eGFR in ml/min/1.73m2 via CKD-Epi equation) ≥ 90 
with albuminuria; 2= 60-89 with albuminuria; 3a= 45-59; G3b= 30-44; 4= 15-29; 5= < 15. 
Projected national estimates are reported using appropriate NHANES weights to 
account for non-response bias and oversampling. RESULTS: Of the 2,006 T2DM indi-
viduals, the overall age-adjusted CKD prevalence from 2007-2012 was 38.3%: 40.2% 
in 2007-2008, 36.9% in 2009-2010, and 37.6% in 2011-2012. Most CKD patients were at 
early stages (77.5% for Stages 1 to 3a), with only 22.5% with moderate to severe CKD 
(Stages 3b to 5). Over the 3 survey cycles, the prevalence of Stage 3a increased while 
Stage 1 and 2 decreased. The prevalence of CKD in patients with T2DM was 25.7% 
in < 65 years old, 58.7% in ≥ 65 years old, 40.0% in males, 38.7% in females, 43.5% 
in both Blacks and Mexican Americans, and 38.7% in Whites. CONCLUSIONS: Our 
findings, in this nationally representative population, highlight that CKD, primarily 
early stages, is prevalent among a large group of T2DM patients, particularly Blacks 
and Mexican-Americans, for whom interventions may be targeted in order to slow 
and/or prevent the progression of kidney function decline. Patients not aggres-
sively targeted for CKD screening, such as younger patients, also warrant attention.
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OBJECTIVES: This study compared hypoglycemia rates in patients with type 2 dia-
betes on metformin who augmented treatment with saxagliptin or glipizide 5-20 
mg/day. METHODS: This retrospective analysis utilized US healthcare claims data 
from the Truven Health MarketScan Research Databases. Data were from adults on 
metformin monotherapy who added saxagliptin or glipizide 5-20 mg/day between 
1 August 2009 and 31 December 2010. Hypoglycemia event rates were compared 
during the 4 months after initiation of saxagliptin or glipizide. A hypoglycemia 
event was defined as a diagnosis of hypoglycemia on an outpatient or emergency 
room claim, a principal diagnosis on a hospital claim, or a glucagon injection 
in an outpatient setting. Analyses were adjusted for patient demographics and 
clinical characteristics using inverse propensity score weights and rate ratios 
were computed using bivariate Poisson regression. To achieve maximal covariate 
balance in adjusted analyses, only patients with a propensity score ≥ 0.02 were 
retained for analysis. RESULTS: A total of 9,246 patients (1,567 taking saxagliptin; 
7,679 taking glipizide) qualified. During 120 days of follow-up, there were 205 
hypoglycemia events. Most of the hypoglycemia events (93.2%) occurred in the 
outpatient setting. There were no inpatient or emergency room hypoglycemia 
events in the saxagliptin cohort. The overall unadjusted rate of hypoglycemia was 
significantly lower in the saxagliptin cohort than in the glipizide cohort (1.74 vs. 
7.73 per 100 person-years; p< 0.001; rate ratio= 0.23 [95% confidence interval= 0.10-
0.44]). After applying inverse propensity score weights (N= 8,241), the adjusted rate 
of hypoglycemia also was significantly lower in the saxagliptin cohort versus the 
glipizide cohort (1.74 vs. 4.18 per 100 person-years; p= 0.002; rate ratio= 0.42 [95% 
confidence interval= 0.24-0.71]). CONCLUSIONS: Treatment with saxagliptin was 
associated with a lower risk of hypoglycemia compared with glipizide 5-20 mg/
day in a real-world database. These results add confidence to similar findings 
from clinical trials.
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OBJECTIVES: Diabetes influences bone metabolism, but the relation of type 1 diabe-
tes mellitus (T1DM) with bone mineral density (BMD) remains inconsistent across 
studies. The objective of this study was to perform a meta-analysis to estimate 
the difference in BMD between T1DM and non-diabetic populations. METHODS: 
Studies were selected by doing comprehensive literature search in PubMed and 
EMBASE up to January 2014. Additional searches were also conducted to include 
research abstracts, cross references and bibliography of individual articles. All stud-
ies, including cross-sectional, cohort or case–control design, showing association 
between T1DM and BMD measured by dual energy X-ray absorptiometry (DEXA) 
were considered eligible for the review. A random effects meta-analysis was per-
formed. Heterogeneity and publication bias were checked. Results are expressed as 
Pearson correlations. RESULTS: The analysis was done on 48 observational studies 
reporting 2,885 cases and 4,814 controls. Meta-analysis showed that BMD in T1DM 
patients was significantly lower, with pooled mean differences of -0.43 (95% CI: 
-0.69, -0.17) in women and -0.25 (95% CI: -0.50, -0.005) in men at the hip region. It 
was also found significantly lower at the spine region [-0.30 (95% CI: -0.47, -0.13)] in 
men and forearm region [-0.21 (95% CI: -0.43, 0.00)] in women. No siginificant differ-
ence was found in BMD (in both men and women) between in case of femoral neck 
region. Sensitivity analysis confirmed the stability of our results. CONCLUSIONS: 
Our analysis confirmed that both men and women with T1DM have preponderence 
to have lower BMD levels. Multiple factors (age/gender/menopausal status/bone 
type) can inﬂuence BMD in individuals with T1DM. Large prospective epidemiologi-
cal studies are required to confirm our findings.
